Who are Consolidation with Brentuximab Vedotin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Brentuximab Vedotin (Bv), Zilovertamab vedotin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/consolidation-with-brentuximab-vedotin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Consolidation with Brentuximab Vedotin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Consolidation with Brentuximab Vedotin (Consolidation with Brentuximab Vedotin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD30-targeting antibody-drug conjugate. Area: Oncology.

phase 2 CD30-targeting antibody-drug conjugate CD30 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Consolidation with Brentuximab Vedotin (Consolidation with Brentuximab Vedotin) — Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea. Antibody-drug conjugate targeting CD30

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Consolidation with Brentuximab Vedotin TARGET	Consolidation with Brentuximab Vedotin	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	phase 2	CD30-targeting antibody-drug conjugate	CD30
Brentuximab Vedotin (Bv)	Brentuximab Vedotin (Bv)	Assistance Publique - Hôpitaux de Paris	marketed	Antibody-drug conjugate (ADC)	CD30
Zilovertamab vedotin	Zilovertamab vedotin	Merck Sharp & Dohme LLC	phase 3	Monoclonal antibody-drug conjugate	CD30

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD30-targeting antibody-drug conjugate class)

Fondazione Italiana Linfomi - ETS · 1 drug in this class
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Consolidation with Brentuximab Vedotin — Competitive Intelligence Brief. https://druglandscape.com/ci/consolidation-with-brentuximab-vedotin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab